John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$244M |
| 2 |
Pfizer
PFE
|
+$234M |
| 3 |
Nike
NKE
|
+$201M |
| 4 |
Tesla
TSLA
|
+$200M |
| 5 |
S&P Global
SPGI
|
+$196M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$305M |
| 2 |
Advanced Micro Devices
AMD
|
+$241M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$231M |
| 4 |
Merck
MRK
|
+$199M |
| 5 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.1% |
| 2 | Healthcare | 11.63% |
| 3 | Consumer Discretionary | 11.09% |
| 4 | Financials | 10.76% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2476
Extra Space Storage
EXR
$30.6B
| $330K | ﹤0.01% |
+2,247
| New | +$328K |
|
2477
Enel Chile
ENIC
$6.32B
| $330K | ﹤0.01% |
108,283
| – | – |
|
2478
Oak Valley Bancorp
OVLY
$287M
| $330K | ﹤0.01% |
13,315
-2,100
| -14% | -$53.5K |
|
2479
GSI Technology
GSIT
$229M
| $329K | ﹤0.01% |
96,835
-25,810
| -21% | -$74.6K |
|
2480
EVI Industries
EVI
$186M
| $329K | ﹤0.01% |
13,214
| – | – |
|
2481
Littelfuse
LFUS
$10.3B
| $329K | ﹤0.01% |
+1,356
| New | +$326K |
|
|
GRTS
2482
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $328K | ﹤0.01% |
127,577
+77,245
| +153% | +$189K |
|
|
PARAP
2483
DELISTED
Paramount Global 5.75% Series A Mandatory Convertible Preferred Stock
PARAP
| $327K | ﹤0.01% |
+23,822
| New | +$379K |
|
2484
West Pharmaceutical
WST
$24.5B
| $327K | ﹤0.01% |
826
-26,647
| -97% | -$9.86M |
|
2485
Charles River Laboratories
CRL
$14.2B
| $325K | ﹤0.01% |
1,200
-300
| -20% | -$71.6K |
|
2486
Simulations Plus
SLP
$372M
| $324K | ﹤0.01% |
7,874
-19,768
| -72% | -$810K |
|
2487
Invesco Biotechnology & Genome ETF
PBE
$407M
| $324K | ﹤0.01% |
+5,000
| New | +$325K |
|
2488
PagSeguro Digital
PAGS
$2.49B
| $323K | ﹤0.01% |
22,646
-323,566
| -93% | -$4.28M |
|
2489
Latham Group
SWIM
$840M
| $323K | ﹤0.01% |
81,611
-62,064
| -43% | -$177K |
|
2490
Invesco S&P SmallCap 600 Pure Value ETF
RZV
$303M
| $323K | ﹤0.01% |
3,000
+200
| +7% | +$20.6K |
|
2491
RCM Technologies
RCMT
$299M
| $322K | ﹤0.01% |
15,091
-590
| -4% | -$16.3K |
|
2492
Stewart Information Services
STC
$2.12B
| $322K | ﹤0.01% |
4,951
-18,470
| -79% | -$1.12M |
|
2493
Nelnet
NNI
$4.61B
| $322K | ﹤0.01% |
3,400
-19,409
| -85% | -$1.71M |
|
2494
Invesco Large Cap Growth ETF
PWB
$2.42B
| $321K | ﹤0.01% |
+3,600
| New | +$305K |
|
|
HSAI
2495
Hesai Group
HSAI
$2.88B
| $321K | ﹤0.01% |
+63,429
| New | +$341K |
|
|
HQL
2496
abrdn Life Sciences Investors
HQL
$659M
| $321K | ﹤0.01% |
+23,540
| New | +$326K |
|
|
AGNT
2497
AGNT Inc
AGNT
$762M
| $318K | ﹤0.01% |
30,800
-73,900
| -71% | -$907K |
|
|
ITIC
2498
Investors Title Co
ITIC
$573M
| $318K | ﹤0.01% |
1,949
-400
| -17% | -$64.2K |
|
2499
Standex International
SXI
$3.69B
| $318K | ﹤0.01% |
1,745
-8,074
| -82% | -$1.3M |
|
2500
Cadeler
CDLR
$2.51B
| $317K | ﹤0.01% |
+17,495
| New | +$308K |
|
Similar funds
John Overdeck's Q1 2024 Portfolio in Review
As of Q1 2024, John Overdeck held 3,518 positions worth $42.6B, down 2.1% from $43.5B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
John Overdeck withdrew a net $4.42B in Q1 2024, closing 532 positions and reducing 1,392 holdings. Its most notable exit was Rivian, an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 18% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, John Overdeck opened a new position in Pfizer worth $234M.
- John Overdeck's largest Q1 2024 buy was Pfizer: 8,419,014 shares worth $234M.
- John Overdeck added most to Gilead Sciences in Q1 2024, an estimated $244M increase.
- John Overdeck's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $305M.
- John Overdeck fully exited Rivian in Q1 2024, selling an estimated $158M.
- John Overdeck's ten largest holdings make up 9% of its $42.6B portfolio in Q1 2024.
- John Overdeck opened 408 new positions and closed 532 in Q1 2024.
- John Overdeck's portfolio value fell 2.1% quarter-over-quarter to $42.6B.
Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.